Lamas-Paz et al. (2025) discovered through data analysis from various patient cohorts and mouse models that the expression level of CDKN1A is significantly associated with non-alcoholic steatohepatitis (NASH), liver fibrosis, and more severe liver diseases such as cirrhosis and hepatocellular carcinoma, with its overexpression exacerbating lipid metabolic disorders and inflammatory responses. The gene discussed is CDKN1A; the disease is metabolic dysfunction-associated steatohepatitis.